Tag Archives: BIO Investor Forum

Hana Biosciences completes private placement

Hana Biosciences (OTCBB:HNAB) has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million. Net proceeds of the offering will be used to support completion of Hana’s pivotal Phase 2 clinical trial (rALLy) of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Podcast with Joyce Cramer, Epilepsy Therapy Project

Biotech-Now’s Tracy Krughoff speaks with Joyce Cramer, president of the Epilepsy Therapy Project about the upcoming BIO Investor Forum and what this advocacy group looks for in terms of companies and projects. Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Targacept announces pricing of common stock offering

Targacept, Inc. (NASDAQ: TRGT) announced that the recently announced underwritten public offering of 2,200,000 shares of its common stock has been priced at a price to the public of $21.00 per share. As previously announced, Deutsche Bank Securities will act as sole manager for the offering and Targacept has granted Deutsche Bank Securities an option to purchase an additional 320,000 shares of common stock to cover over-allotments, if any. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical antifungal agent, in patients with tinea pedis (athlete’s foot). The study assessed the effectiveness of luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Long-term immune response for Vical’s TransVax™ vaccine in Phase 2 trial

Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,